Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com

June 6, 2024

Advancing Molecular Diagnostics Through Strategic Collaboration

ANN ARBOR, MI, JUNE 5, 2024—Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of which are multiplex assays, including panels for wound, upper respiratory, urinary tract, and sexually transmitted infections.


“We are delighted to be partnering with Cayman Chemical to provide our portfolio of assays worldwide,” said shared company founder and CEO, John SantaLucia. “Cayman has a long-standing and exceptional breadth of products offered to the research community, and we’re enthusiastic about adding further value for researchers.” PCRassays.com’s line of products has been designed using DNA Software, the industry-leading multiplex design software. Multiplex PCR kits save researchers time and expenses by allowing for simultaneous detection, minimal enzyme amounts, and high-throughput analysis.


PCRassays.com is based out of Plymouth, MI and one of the many biotechnology companies representing Michigan, making this a growing hub for the life sciences. “We are honored and proud to be a part of a consortium of Michigan-based companies impacting the life sciences ecosystem in a meaningful way,” added Dr. SantaLucia. “We have engineered our enzyme formulations with Fortis (Empirical Biosciences), collaborated with the State of Michigan Department of Health and Human Services for the development of a novel assay, and have now partnered with Cayman Chemical, the leading Michigan-based company supplying life science reagents for researchers worldwide.”


About Cayman Chemical

Cayman Chemical helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, we offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic. Learn more at www.caymanchem.com.


About PCRassays.com
PCRassays.com provides multiplexed research use only qPCR kits for the detection of human pathogens, food borne pathogens, wastewater surveillance, and research-based applications. PCRassays.com offers flexible multiplex configurations and has an automated design platform (DNA Software) for ever changing market dynamics. The team at PCRassays.com has world-leading expertise in nucleic hybridization, structure folding, and thermodynamics. In addition to our assays, we offer client services for custom assay design and development.

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.